-

Hims & Hers to Announce Fourth Quarter and Full Year 2025 Financial Results on February 23, 2026

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), the leading health and wellness platform, today announced that it will report fourth quarter and full year 2025 financial results after the market closes on Monday, February 23, 2026. The company will host a live conference call to discuss the results at 5:00 p.m. ET the same day.

The conference call can be accessed by dialing (888) 510-2630 for U.S. participants and (646) 960-0137 for international participants, referencing conference ID 1704296. A live audio webcast will be available at https://investors.hims.com and will be archived for one year.

Upcoming Conference Participation

Hims & Hers also announced that members of the company’s management team will be participating in the Morgan Stanley Technology, Media & Telecom Conference on March 2, 2026 in San Francisco.

About Hims & Hers Health, Inc.

Hims & Hers is the leading health and wellness platform on a mission to help the world feel great through the power of better health.

We believe how you feel in your body and mind transforms how you show up in life. That’s why we’re building a future where nothing stands in the way of harnessing this power. Hims & Hers normalizes health & wellness challenges—and innovates on their solutions—to make feeling happy and healthy easy to achieve. No two people are the same, so the Company provides access to personalized care designed for results.

For more information, please visit https://investors.hims.com/.

Contacts

Investor Relations

Bill Newby
Investors@forhims.com

Media Relations

Abby Reisinger-Moley
Press@forhims.com

Hims & Hers

NYSE:HIMS

Release Versions

Contacts

Investor Relations

Bill Newby
Investors@forhims.com

Media Relations

Abby Reisinger-Moley
Press@forhims.com

More News From Hims & Hers

Hims & Hers Launches Peptides+, a New Clinically-Guided Specialty for Access to Personalized, Proactive Health

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers (NYSE: HIMS) today announced the launch of Peptides+, a new specialty built around clinically-guided protocols designed to target health at the cellular level. After a clinical visit with a licensed provider, eligible customers may be prescribed a personalized treatment plan including up to five treatments at launch: Sermorelin, NAD+, Glutathione, Vitamin B12, and L-Carnitine, depending on their needs as determined by their provider. Access to BPC...

Dr. Andrew Huberman Joins Hims & Hers Board of Directors

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), the leading global health and wellness platform, announced the appointment of Andrew Huberman, Ph.D., to the company’s Board of Directors. Dr. Huberman is a world-renowned neuroscientist and tenured professor in the Departments of Neurobiology and Ophthalmology at Stanford University School of Medicine. He has authored or co-authored more than 75 peer-reviewed articles in respected scientific journals...

Hims & Hers Health, Inc. Reports Third Quarter 2026 Financial Results

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”, NYSE: HIMS), the leading global health and wellness platform, today announced financial results for the third quarter ended September 30, 2026. “In healthcare, whoever owns the customer relationship wins, and that’s exactly what we’re building toward at Hims & Hers. Today, customers want real choice, real value, and a care team that knows them,” said Andrew Dudum, co-founder and CEO. “Everythin...
Back to Newsroom